DIAGNOS Inc. (CVE:ADK – Get Free Report)’s share price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of C$0.31 and traded as low as C$0.28. DIAGNOS shares last traded at C$0.29, with a volume of 220,250 shares changing hands.
DIAGNOS Trading Down 14.5%
The firm has a 50 day moving average price of C$0.41 and a 200 day moving average price of C$0.31. The stock has a market capitalization of C$28.44 million, a PE ratio of -5.87 and a beta of 0.05. The company has a quick ratio of 0.68, a current ratio of 1.49 and a debt-to-equity ratio of 204.05.
Insider Buying and Selling at DIAGNOS
In related news, Director Robert Dunn purchased 105,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were bought at an average price of C$0.48 per share, for a total transaction of C$50,400.00. Following the acquisition, the director owned 2,679,920 shares of the company’s stock, valued at approximately C$1,286,361.60. This represents a 4.08% increase in their position. Company insiders own 16.81% of the company’s stock.
About DIAGNOS
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.
Featured Articles
- Five stocks we like better than DIAGNOS
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.
